Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
Årsomsättningen för Leqembi® översteg 500 miljoner euro – andra försäljningsmilstolpen uppnådd
Regulatory Filings
2026-04-29 Swedish
Leqembi® annual sales exceed EUR 500 million – second sales milestone achieved
Regulatory Filings
2026-04-29 English
Försäljningen av Leqembi® uppgick till 26,2 miljarder yen under det första kvartalet 2026
Regulatory Filings
2026-04-29 Swedish
Sales of Leqembi® totaled 26.2 billion yen in the first quarter 2026
Earnings Release Classification · 1% confidence The document is a press release announcing preliminary first quarter 2026 sales figures for Leqembi® and the resulting royalty to BioArctic. It provides key highlights of Q1 results (sales and royalty numbers) without full financial statements or detailed analysis. This matches the definition of an Earnings Release (ER): an initial announcement of quarterly financial results with highlights only. Q1 2026
2026-04-29 English
Notice of Annual General Meeting 2026 in BioArctic AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice to shareholders of BioArctic AB’s Annual General Meeting 2026, including the meeting date, venue, registration instructions, voting procedures (postal voting, proxy), detailed agenda items, board and auditor elections, dividend proposal, and other resolutions. It is not a presentation made during the AGM (AGM-R), nor the full annual report (10-K), nor an earnings release (ER), nor a results declaration (DVA). Instead, it constitutes the proxy solicitation/information materials sent to shareholders to request their votes and inform them of proposals. Therefore, it fits the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-21 English
Kallelse till årsstämma 2026 i BioArctic AB (publ)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice (kallelse) to shareholders for the 2026 Annual General Meeting of BioArctic AB (publ). It provides meeting date, registration details, agenda with proposals, voting instructions (including proxy and postal voting procedures), and items requiring shareholder approval. This aligns with the definition of a Proxy Solicitation & Information Statement (PSI), i.e. materials sent to shareholders to inform them of agenda items and solicit their votes for an upcoming meeting.
2026-04-21 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.